1. A decorating device for decorating vehicle-interior components, of which a laser is irradiated onto the decorating surface of a resin compact or onto the decorating surface of a coat-layer formed on the resin compact to draw designs thereon that are made of the linear laser-processed part, and that the laser focal-point is shifted from the decorating surface so as to draw the designs, thus forming the gradation on a certain part of the whole design, with the decorating device being characterized in comprising a data-preparing device for preparing the drawing-data on a virtual decorating surface that is deformed so as to have a different curvature than the surface shape of the actual decorating surface, and that a laser-drawing device for forming the gradation by emitting a laser focused on the virtual decorating surface is based on the drawing-data prepared by the data-preparing device, thus conducting the laser-processing with the laser-focal point shifted from the actual decorating surface.
2. A decorating device for vehicle-interior components according to claim 1, characterized in that the laser-drawing device has functions for scanning the laser-focal point in the surface-direction on the decorating surface of the resin compact and for adjusting the focal point in the vertical-direction of the decorating surface, and that in moving the laser-focal point in the surface-direction, the laser-drawing device, based on the drawing-data, increases the focal-shift amount in the vertical-direction against the unit length in the surface-direction at the starting point of the gradation region that is connected to the provided non-gradation drawing region and gradually reduces the focal-shift amount toward the ending point of the gradation region that is away from the drawing area, thus forming the gradation on the laser-processed part of the gradation region.
3. A decorating device for vehicle-interior components according to claim 1, characterized in that the virtual-decorating surface is positioned at the side of the laser-drawing device rather than on the actual decorating surface.
4. A decorating device for vehicle-interior components according to claim 1, characterized in that the laser-drawing device draws the designs by forming the concave laser-processed part.
5. A decorating device for vehicle interior components according to claim 1, characterized in that the laser-drawing device draws the designs by forming the convex laser-processed part on the decorating surface.
6. A decorating device for vehicle interior components according to claim 1, characterized in that the laser-drawing device draws the designs by changing the color of either the coat layer surface or the component surface.
7. A decorating method for vehicle-interior components, by which a laser is irradiated onto the decorating surface of a resin compact or onto the decorating surface of a coat layer formed on the resin compact to draw thereon designs that are made within the linear laser-processed area, and that the laser focal point is shifted from the decorating surface to draw the designs, thus forming gradation on part of the whole design, characterized in that in shifting the laser focal point in the surface-direction of the decorating surface within the gradation region to provide gradation on the designs of the decorating surface, the focal-shift amount in the vertical-direction against the unit length in the surface-direction is greater at the starting point of the gradation region and gradually less toward the ending point of the gradation region, thus forming the gradation on the laser-decorating part of the gradation region.
8. A decorating method for vehicle interior components according to claim 7, characterized in that a concave laser-processed part is formed by the laser irradiation, thus drawing the design thereon.
9. A decorating method for vehicle interior components according to claim 7, characterized in that a convex laser-processed part is formed on the decorating surface by the laser irradiation, thus drawing the design thereon.
10. A decorating method for vehicle interior components according to claim 7, characterized in that the color of either the coat layer surface or the component surface is changed by the laser irradiation, thus drawing the design thereon.
11. A vehicle-interior component on which the design is drawn by using the decorating device according to claim 1 above, characterized in that the gradation is provided on the design drawn on the decorating surface with a reduction in the height or depth of the laser-processed part by a certain ratio all the way from the starting point to the ending point of the gradation region.
12. A vehicle-interior component according to claim 11, characterized in that the linear laser-processed part is formed according to the changes of the condition of the decorating surface, and the gradation is provided by a certain ratio of the reduction in the width of the laser processing part.
13. A vehicle-interior component according to claim 11, characterized in that the decorating surface is a flat surface.
14. A vehicle-interior component according to claim 11, characterized in that the decorating surface has a curved surface.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A compound of Formula I:
20
X is O, NCH, CR7CH or CR7N, in which R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
Z is O, S or NR8, in which R8 is hydrogen or alkyl of 1 to 6 carbon atoms;
R1, R5 and R6 are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;
R2 is hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;
R3 and R4 are, independently, hydrogen or alkyl of 1 to 6 carbon atoms;
n is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein X is CR7CH where R7 is hydrogen or alkyl of 1 to 3 carbon atoms.
3. A compound according to claim 1 of Formula Ia:
21
or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 of Formula Ib:
22
or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1, wherein R1 is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
6. A compound according to claim 1, wherein R1 is hydrogen, halo or alkoxy of 1 to 6 carbon atoms.
7. A compound according to claim 1, wherein R1 is hydrogen.
8. A compound according to claim 1, wherein R2 is hydrogen, amino or alkyl of 1 to 6 carbon atoms.
9. A compound according to claim 1, wherein R2 is hydrogen or alkyl of 1 to 3 carbon atoms.
10. A compound according to claim 1, wherein R3 and R4 are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms.
11. A compound according to claim 1, wherein R4 is hydrogen.
12. A compound according to claim 1, wherein R7 and R8 are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms.
13. A compound according to claim 1, wherein R5 and R6are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms.
14. A compound according to claim 1, wherein R5 and R6are independently selected from hydrogen, cyano or halogen.
15. A compound according to claim 1, wherein Z is NR8 .
16. A compound according to claim 15, wherein R8 is hydrogen or alkyl of 1 to 3 carbon atoms.
17. A compound according to claim 1, wherein n is 2 or 3.
18. A compound according to claim 1, wherein R1 hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
19. A compound according to claim 1, wherein R1 is hydrogen, halo or alkoxy of 1 to 6 carbon atoms, R2, R3, R7 and R8 are hydrogen or alkyl of 1 to 3 carbon atoms, R4 is hydrogen, R5 and R6 are independently hydrogen, cyano or halogen, Z is NR8 and n is 2 or 3.
20. A compound according to claim 1, wherein said compound is N-2-(5-methoxy-1H-indol-3-yl)-ethyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
21. A compound according to claim 1, wherein said compound is N-2-(5-chloro-1H-indol-3-yl)ethyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
22. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
23. A compound according to claim 1, wherein said compound is N-2-(5-fluoro-1H-indol-3-yl)ethyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
24. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1H-indol-3-yl)propyl-N-(8-ethyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
25. A compound according to claim 1, wherein said compound is N-3-(1 H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
26. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1H-indol-3-yl)propyl-N-methyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
27. A compound according to claim 1, wherein said compound is N-3-(7-fluoro-1H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
28. A compound according to claim 1, wherein said compound is N-4-(1 H-indol-3-yl)butyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
29. A compound according to claim 1, wherein said compound is N-4-(5-fluoro-1H-indol-3-yl)butyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
30. A compound according to claim 1, wherein said compound is N-4-(5-fluoro-1H-indol-3-yl)-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)butan-2-amine or a pharmaceutically acceptable salt thereof.
31. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
32. A compound according to claim 1, wherein said compound is N-3-(5,7-difluoro-1H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
33. A compound according to claim 1, wherein said compound is N-(2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-N-3-(5-fluoro-1H-indol-3-yl)propylamine or a pharmaceutically acceptable salt thereof.
34. A compound according to claim 1, wherein said compound is N-(2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-N-3-(5-fluoro-1H-indol-3-yl)propyl-N-methylamine or a pharmaceutically acceptable salt thereof.
35. A compound according to claim 1, wherein said compound is N-3-(5,7-difluoro-1H-indol-3-yl)propyl-N-methyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
36. A compound according to claim 1, wherein said compound is N-2-(1-benzofuran-3-yl)ethyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
37. A compound according to claim 1, wherein said compound is N-3-(1-benzofuran-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
38. A compound according to claim 1, wherein said compound is N-3-(7-methoxy-1-benzofuran-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
39. A compound according to claim 1, wherein said compound is N-3-(1-benzothien-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
40. A compound according to claim 1, wherein said compound is N-2-(1-benzothien-3-yl)ethyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
41. A compound according to claim 1, wherein said compound is N-3-(1-benzothien-3-yl)propyl-N-methyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
42. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1H-indol-3-yl)propyl-N-(2-methyl-7,8-dihydro-1,4dioxino2,3-g1,3benzoxazol-8-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
43. A compound according to claim 1, wherein said compound is N-3-(5-fluoro-1H-indol-3-yl)propyl-N-methyl-N-(2-methyl-7,8-dihydro-1,4dioxino2,3-g1,3benzoxazol-8-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
44. A compound according to claim 1, wherein said compound is N-ethyl-N-3-(5-Fluoro-1H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
45. A compound according to claim 1, wherein said compound is N-3-(5,7-difluoro-1-methyl-1 H-indol-3-yl)propyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
46. A compound according to claim 1, wherein said compound is N-3-(5,7-difluoro-1-methyl-1 H-indol-3-yl)propyl-N-methyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
47. A compound according to claim 1, wherein said compound is N-4-(1-benzofuran-3-yl)butyl-N-(8-methyl-2,3-dihydro-1,4dioxino2,3-flquinolin-2-ylmethyl)amine or a pharmaceutically acceptable salt thereof.
48. A compound according to claim 1, wherein said compound is 3-3-(8-methyl-2,3-dihydro-1,4dioxino2,3-flquinolin-2-ylmethyl)-amino-propyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
49. A compound according to claim 1, wherein said compound is 3-3-(2-methyl-7,8-dihydro-1,4dioxino2,3-g(1,3benzoxazol-8-ylmethyl)amino-propyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
50. A compound according to claim 1, wherein said compound is 3-3-methyl-(2-methyl-7,8-dihydro-1,4dioxino2,3-g1,3benzoxazol-8-ylmethyl)-amino-propyl-1 H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
51. A compound according to claim 1, wherein said compound is 3-3-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amino-propyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
52. A compound according to claim 1, wherein said compound is 3-(6-fluoro-indol-1-yl)-propyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
53. A compound according to claim 1, wherein said compound is 3-(6-fluoro-indol-1-yl)-propyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
54. A compound according to claim 1, wherein said compound is 4-(5-fluoro-1 -methyl-1H-indol-3-yl)-butyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
55. A compound according to claim 1, wherein said compound is ethyl-3-(5-fluoro-1H-indol-3-yl)-propyl-(2-methyl-7,8-dihydro-1,4dioxino2,3-g1,3benzoxazol-8-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
56. A compound according to claim 1, wherein said compound is 1-methyl-3-3-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amino-propyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable slat thereof.
57. A compound according to claim 1, wherein said compound is 4-(6-fluoro-indol-1-yl)-butyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
58. A compound according to claim 1, wherein said compound is 3-4-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amino-butyl-1 H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
59. A compound according to claim 1, wherein said compound is 1-methyl-3-3-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amino-propyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
60. A compound according to claim 1, wherein said compound is 3-4-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amino-butyl-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
61. A compound according to claim 1, wherein said compound is 3-(5-fluoro-1-methyl-1H-indol-3-yl)-propyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
62. A compound according to claim 1, wherein said compound is 4-(5-fluoro-1H-indol-3-yl)-butyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
63. A compound according to claim 1, wherein said compound is 4-(5-fluoro-1-methyl-1H-indol-3-yl)-butyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
64. A compound according to claim 1, wherein said compound is (3-(5-fluoro-1H-indol-3-yl)-propyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-propyl-amine or a pharmaceutically acceptable salt thereof.
65. A compound according to claim 1, wherein said compound is 3-(4-fluoro-indol-1-yl)-propyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
66. A compound according to claim 1, wherein said compound is 4-(6-fluoro-indol-1-yl)-butyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
67. A compound according to claim 1, wherein said compound is 3-(4-fluoro-indol-1-yl)-propyl-methyl-(8-methyl-2,3-dihydro-1,4dioxino2,3-fquinolin-2-ylmethyl)-amine or a pharmaceutically acceptable salt thereof.
68. A compound according to claim 1, wherein said compound is N-4(5-Chloro-1-benzothien-3-yl)butyl-N-(2S)-8-methyl-2,3-dihydro1,4dioxino2,3-fquinolin-2-ylmethylamine or a pharmaceutically acceptable salt thereof.
69. A compound according to claim 1, wherein said compound is N-3-(5-Chloro-1-benzothien-3-yl)propyl-N-(2S)-8-methyl-2,3-dihydro1,4dioxino2,3-fquinolin-2-ylmethylamine or a pharmaceutically acceptable salt thereof.
70. A compound according to claim 1, wherein said compound is N-3-(5-Fluoro-1-benzothien-3-yl)propyl-N-(2S)-8-methyl-2,3-dihydro1,4dioxino2,3-fquinolin-2-ylmethylamine or a pharmaceutically acceptable salt thereof.
71. A compound according to claim 1, wherein said compound is N-4-(1-Benzofuran-3-yl)butyl-N-ethyl-N-(2S)-8-methyl-2,3-dihydro1,4dioxino2,3-fquinolin-2-ylmethylamine or a pharmaceutically acceptable salt thereof.
72. A compound according to claim 1, wherein said compound is the S enantiomer, substantially free of the R enantiomer of said compound.
73. A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, comprising the step of:
administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
74. A method according to claim 73, wherein the condition is depression.
75. A method according to claim 73, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
76. A pharmaceutical composition, comprising:
an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier or excipient.